LONDON: US drugmaker Pfizer pressed the scientific case for its controversial plan to acquire AstraZeneca as its chief executive prepared for a grilling from British lawmakers.
In the latest phase of Pfizer’s campaign to counter critics of its proposed US$106bil deal, research head Mikael Dolsten said he had been through five different mergers and acquisitions and denied such big transactions disrupted drug research.
Already a subscriber? Log in
Save 30% OFF The Star Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
